广告
加载中

四部门通报纸尿裤调查结果:国内全部168家生产企业样品均未检出甲酰胺

亿邦动力 2026-10-16 09:01
亿邦动力 2026/10/16 09:01

邦小白快读

EN
全文速览

总:官方通报给出明确结论:国内全部168家婴幼儿纸尿裤生产企业的产品均未检出甲酰胺,纸尿裤安全性得到权威确认。

1.权威抽检覆盖全面:共抽检180个品牌368批次成品,并对腰围、粘扣等关键部位另检32批次,结果全部未检出甲酰胺。

2.自媒体博主的检测不靠谱:对小红书博主“靠谱老王”剩余样品复检,58批次未检出;其检测方法未做方法确认,数据评估有偏差,结论无法成立。

3.血液甲酰胺检测不可信:山东质谱中心检测存在信噪比不足、人为取舍数据、删除原始数据等问题,210份血液样本复检均未检出。

4.生产企业全部合规:168家企业现场检查均符合消毒产品卫生规范,未发现生产工艺和原材料中添加甲酰胺。

建议:购买纸尿裤不必恐慌,多认准正规品牌和官方渠道,遇到耸人听闻的测评先看权威通报。

总:四部门联合通报相当于国家层面对全行业的质量背书,品牌商应抓住这一信任修复窗口,强化安全心智。

1.品牌营销:将“368批次全部未检出”“无甲酰胺”作为沟通点,但宣传需严格基于通报原文,避免扩大化表述。

2.渠道建设:通报后经销商和母婴渠道更看重合规证明,品牌商可主动提供检测报告、生产资质,提升进场谈判力。

3.价格竞争:安全事件平息后,消费者更愿意为有质量背书的品牌支付溢价,中高端定位产品有机会,但不要借机炒作。

4.产品研发:继续严控原材料,尤其腰围、粘扣等接触部位,建立可追溯的质量档案,把检测嵌入研发流程。

5.用户行为:消费者对自媒体测评的戒备上升,对官方通报和权威检测的信任上升,品牌可通过透明化工厂、定期披露第三方抽检结果来稳定用户。

总:官方通报是对行业的重大利好,纸尿裤品类的负面舆情被权威澄清,卖家可围绕消费信心恢复调整策略。

1.政策解读:监管层对婴幼儿用品保持高强度抽样和现场检查,合规是经营底线,未来质量抽检只会更严。

2.增长市场:通报消除了安全隐患疑虑,纸尿裤作为刚需品类,短期被压制的需求可能回补,大促和日常销售都可积极备货。

3.消费需求变化:消费者会更关注“无甲酰胺”“权威检测”等安全标签,商品详情页可增加通报结论和检测报告截图,降低决策门槛。

4.事件应对:若店铺遇到恶意差评或旧闻炒作,可利用官方通报进行申诉和客服话术澄清,不要沉默。

5.风险提示:网红测评不等于事实,卖家不宜引用自媒体未经证实的检测结论做促销,反而可能触犯广告法;注意保留进货凭证和批次检测报告备查。

总:调查覆盖全部168家生产企业,工厂在此次舆情中被证明整体合规,但质量管理和溯源能力仍需持续加强。

1.产品设计需求:通报重点检测腰围、粘扣等部位,提示工厂在辅料选择、胶粘工艺上要确保不含甲酰胺,并保留配方和原料清单。

2.生产规范:现场检查依据消毒产品生产企业卫生规范,工厂必须持续满足车间洁净、人员卫生、物料仓储等要求,这是不被处罚的基本盘。

3.原材料管控:未检出甲酰胺不等于可以放松,应建立供应商审核和来料检测制度,防止个别批次因原料波动出现问题。

4.数字化质量管理启示:舆情事件说明生产过程留痕很重要,可引入批次追溯系统,将原料、生产、检测数据关联,一旦被质疑能快速提供证据。

5.商业机会:权威检测机构资源紧缺,工厂可与有资质的第三方检测机构建立长期合作,把送检从被动应对变成日常质量展示。

总:这次通报暴露了检测方法不严谨、数据管理混乱等大量专业问题,为检测机构、数据服务商和企业服务商带来明确的客户痛点与改进方向。

1.客户痛点:自媒体博主和部分检测公司因方法未确认、未做空白样或平行样、删除原始数据被官方点名,客户对检测结果的公信力产生质疑,服务商需要确保检测流程可复现、可审计。

2.解决方案:提供符合标准的方法确认和验证服务,帮助企业和检测实验室建立原始数据留痕、电子化记录和三级审核机制,杜绝人为删改。

3.解决方案:针对纸尿裤等母婴品类,开发包括成品、分部位(腰围、粘扣)在内的专项甲酰胺检测方案,用更细颗粒度的检测赢取客户。

4.行业趋势:监管层正在严查不实检测,检测行业将从“出报告”竞争转向“方法和数据可靠性”竞争,服务商应提前打造数据合规能力。

5.新技术:质谱检测的定性和定量方法还有空白,有机质谱、数据处理算法等领域存在研发和咨询服务机会。

总:纸尿裤甲酰胺舆情主要由小红书、抖音等平台上的自媒体测评视频引爆,平台在内容治理和母婴类目运营上需要采取更主动的动作。

1.内容审核:对涉及“有毒”“检出”等高风险健康指控的测评内容,应要求博主提供完整的检测资质、方法依据和原始数据,无法提供的不予推荐或限流。

2.风向规避:对未经权威确认的检测报告截图、视频建立举报和快速下架机制,避免舆情二次扩散,同时防止用户被误导。

3.商家保护:被误伤的纸尿裤商家可借助官方通报申诉恢复权重,平台应开通舆情澄清通道,把误判限流、下架的商品及时恢复。

4.类目运营:母婴类目的商品详情页可增加“官方抽检结果”信息栏,与监管部门数据打通,让合规商家获得信任标识。

5.招商合作:鼓励第三方检测机构成为平台合作伙伴,为商家提供抽检、验货服务,平台可以建立检测报告验真入口,提升整体品控形象。

总:此次事件是观察中国母婴用品监管和舆情治理的典型样本,暴露出产品检测标准、医疗检测研究、第三方检测机构管理等多方面短板。

1.产业新动向:官方对全行业168家企业全覆盖抽检,并创新地对腰围、粘扣等重点部位进行分析,这种“全行业覆盖加重点部位”的监管方法值得继续研究。

2.新问题:多家检测机构出现方法未确认、匹配度只有7%、删除原始数据等问题,说明第三方检测行业存在严重的方法学乱象,需要建立执业资质和操作规范。

3.检测方法启示:舆情中使用的检测方法不能简单等同于法定方法,必须经过方法确认、空白样和平行样、信噪比评估、数据保留等程序;质谱数据分析的偏差评估有待国家层面给出统一指南。

4.血液检测研究:山东质谱中心在方法未成熟时就对外发布结果,提示临床研究和公共沟通的伦理边界需要制度约束,罕见检测指标应经过伦理审查和结果复核。

5.政策法规建议:可考虑制定儿童用品中甲酰胺的限量标准和统一检测标准,明确自媒体送检和发布健康风险声明的责任边界,并建立重大舆情的快速科学响应机制。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Overall: The official notification gives a clear conclusion: all 168 domestic infant diaper manufacturers had no formamide detected in their products, and diaper safety has been authoritatively confirmed.

1. Authoritative sampling was comprehensive: 180 brands and 368 batches of finished products were tested, with another 32 batches of key parts such as waistbands and fastening tapes also tested; no formamide was found in any sample.

2. The self-media blogger's testing was unreliable: re-testing of remaining samples from Xiaohongshu blogger "Lao Wang Kaopu" found no formamide in 58 batches; the testing method had not been validated, the data evaluation was biased, and the conclusions could not stand.

3. Blood formamide testing was not credible: the Shandong Mass Spectrometry Center's tests had problems such as insufficient signal-to-noise ratio, selective data handling, and deleted raw data; re-testing of 210 blood samples found no formamide.

4. All production enterprises were compliant: on-site inspections of 168 enterprises met the hygiene standards for disinfection products, and no formamide was found to be added in production processes or raw materials.

Suggestion: There is no need to panic when buying diapers. Choose reputable brands and official channels, and check authoritative notifications before believing alarming product reviews.

Overall: The joint notification by four government departments is equivalent to a national-level quality endorsement for the entire industry. Brand owners should seize this window to rebuild trust and strengthen the safety mindset.

1. Marketing: Use messages such as "all 368 batches detected no formamide" and "formamide-free" in communications, but strictly based on the original notification and avoid overstated claims.

2. Channel development: After the notification, distributors and maternal-child channels place more value on compliance proof. Brand owners can proactively provide test reports and production qualifications to improve negotiation power.

3. Price competition: With safety concerns settled, consumers are more willing to pay a premium for brands with quality endorsement. Mid-to-high-end products have opportunities, but brands should not exploit the issue for hype.

4. Product development: Continue strict control over raw materials, especially contact parts such as waistbands and fastening tapes; build traceable quality files and embed testing into the R&D process.

5. User behavior: Consumer caution toward self-media reviews is rising, while trust in official announcements and authoritative testing is rising. Brands can stabilize users through factory transparency and regular disclosure of third-party sampling results.

Overall: The official notification is a major positive for the industry. Negative public opinion about diapers has been authoritatively clarified, and sellers can adjust their strategies based on recovering consumer confidence.

1. Policy interpretation: Regulators maintain high-intensity sampling and on-site inspections for infant products. Compliance is the baseline, and quality inspections will only become stricter.

2. Growth market: The notification removes safety concerns. Diapers are a staple category, so short-term suppressed demand may rebound; sellers can actively stock up for promotions and daily sales.

3. Changing consumer demand: Consumers will pay more attention to safety labels such as "no formamide" and "authoritative testing." Product pages can include official notification conclusions and test report screenshots to lower decision barriers.

4. Incident response: If stores face malicious reviews or recycled old news, use the official notification to appeal and clarify in customer service scripts; do not stay silent.

5. Risk warning: Influencer reviews are not facts. Sellers should not use unverified self-media testing conclusions for promotion, as this may violate advertising law; keep purchase vouchers and batch test reports for verification.

Overall: The investigation covered all 168 production enterprises. Factories were found to be generally compliant during this public opinion crisis, but quality management and traceability capabilities still need continuous strengthening.

1. Product design needs: The notification highlighted testing of waistbands and fastening tapes, reminding factories to ensure formamide-free auxiliary materials and adhesive processes, and to keep formulas and raw material lists on file.

2. Production compliance: On-site inspections followed the hygiene standards for disinfection product manufacturers. Factories must continuously meet requirements for clean workshops, personnel hygiene, and material storage. This is the baseline for avoiding penalties.

3. Raw material control: No formamide detection does not mean standards can be relaxed. Factories should establish supplier audits and incoming-material testing to prevent batch variations from causing problems.

4. Digital quality management: The incident shows that production process records are important. Factories can introduce batch traceability systems linking raw materials, production, and test data, so they can quickly provide evidence when questioned.

5. Business opportunity: Authoritative testing institutions are in short supply. Factories can build long-term partnerships with qualified third-party testing labs and turn sending samples for testing from passive response into everyday quality demonstration.

Overall: The notification exposed many professional problems, including lax testing methods and chaotic data management. It defines clear client pain points and improvement directions for testing agencies, data service providers, and enterprise service providers.

1. Client pain points: Self-media bloggers and some testing companies were officially named for unvalidated methods, missing blank or duplicate samples, and deleting raw data. Clients now question the credibility of test results, so service providers must ensure testing processes are reproducible and auditable.

2. Solutions: Provide method validation and verification services that meet standards; help companies and testing laboratories establish raw data retention, electronic records, and three-level review mechanisms to prevent human tampering.

3. Solutions: For mother-and-baby categories such as diapers, develop specialized formamide testing plans covering finished products and separate parts such as waistbands and fastening tapes, winning clients with finer granularity.

4. Industry trend: Regulators are cracking down on false testing. The testing industry will shift from competition over issuing reports to competition over method and data reliability. Service providers should build data compliance capabilities in advance.

5. New technology: There are still gaps in qualitative and quantitative mass spectrometry methods. Opportunities exist in organic mass spectrometry, data processing algorithms, and related R&D and consulting services.

Overall: The diaper formamide controversy was mainly triggered by self-media testing videos on platforms such as Xiaohongshu and Douyin. Platforms need to take more proactive action in content governance and mother-and-baby category operations.

1. Content review: For testing content involving high-risk health claims such as "toxic" or "detected," require bloggers to provide complete testing qualifications, method basis, and raw data; otherwise do not recommend or limit distribution.

2. Controlling misinformation: Establish mechanisms for reporting and quickly removing unverified test report screenshots or videos to avoid secondary spread of the controversy and prevent users from being misled.

3. Merchant protection: Diaper merchants affected by false claims can use the official notification to appeal and restore ranking. Platforms should open channels for public clarification and restore mistargeted limited or removed products.

4. Category operations: Add an "official sampling results" information block to product pages in the mother-and-baby category, connect with regulatory data, and give compliant merchants a trust badge.

5. Partnerships: Encourage third-party testing agencies to become platform partners, provide sampling and inspection services for merchants, and establish a test report verification portal to improve overall quality control image.

Overall: This incident is a typical sample for observing China's mother-and-baby product regulation and public opinion governance. It exposes weaknesses in product testing standards, medical testing research, and third-party testing agency management.

1. Industry trends: The government conducted full-industry coverage testing across 168 enterprises and innovatively analyzed key parts such as waistbands and fastening tapes. This regulatory approach of "full-industry coverage plus key-part analysis" deserves further study.

2. New problems: Several testing institutions showed unvalidated methods, a matching rate of only 7%, and deleted raw data. This indicates serious methodological chaos in the third-party testing industry, requiring professional qualifications and operational standards.

3. Testing method implications: Methods used in public opinion testing cannot be simply equated with legal methods. They must go through method validation, blank and duplicate samples, signal-to-noise ratio assessment, and data retention. National-level unified guidance is needed for mass spectrometry data bias evaluation.

4. Blood testing research: Shandong Mass Spectrometry Center released results before the method was mature, which shows that ethical boundaries in clinical research and public communication need institutional constraints. Rare testing indicators should undergo ethical review and result verification.

5. Policy and regulatory recommendations: Consider setting limit standards and unified testing standards for formamide in children's products, clarify the responsibility boundaries for self-media testing and publishing health risk claims, and establish a rapid scientific response mechanism for major public opinion incidents.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】10月15日消息,市场监管总局、工业和信息化部、国家卫生健康委、国家疾控局联合调查组发布了关于婴幼儿纸尿裤甲酰胺问题调查核实情况的通报。

舆情发生后,国家疾控局组织各地疾控部门对国内全部168家婴幼儿纸尿裤生产企业(含代工企业)进行全面抽检,共抽检180个品牌368批次纸尿裤成品样品,委托中国疾病预防控制中心、中国质量检验检测科学研究院等权威检测机构进行检测。同时,对部分重点品牌婴幼儿纸尿裤的腰围、粘扣等重点部位开展了32批次分部位检测。根据检测结果,368批次成品样品和32批次分部位样品,均未检出甲酰胺。

调查组也针对上述168家企业进行了现场监督检查。从检查情况看,受检企业均符合消毒产品生产企业卫生规范要求,未发现生产工艺及原材料中存在添加或含有甲酰胺的情况。

此外,通报还公开了针对舆情相关自媒体账号、检测机构的调查结果,确认了其中检测方法不严谨、存在评估偏差等问题。

以下为通报原文:

市场监管总局、工业和信息化部、国家卫生健康委、国家疾控局联合调查组关于婴幼儿纸尿裤甲酰胺问题调查核实情况的通报

2026年6月22日,市场监管总局、工业和信息化部、国家卫生健康委、国家疾控局针对舆情反映的婴幼儿纸尿裤甲酰胺问题成立联合调查组,坚持实事求是,认真核实线索,赴多地开展现场调查核实和研究论证,全面深入开展调查工作。目前,调查工作已结束,现将调查情况通报如下:

一、关于舆情反映的纸尿裤中甲酰胺检测问题

(一)对婴幼儿纸尿裤产品开展监督抽检。舆情发生后,国家疾控局组织各地疾控部门对国内全部168家婴幼儿纸尿裤生产企业(含代工企业)进行全面抽检,共抽检180个品牌368批次纸尿裤成品样品,委托中国疾病预防控制中心、中国质量检验检测科学研究院等权威检测机构进行检测。同时,对部分重点品牌婴幼儿纸尿裤的腰围、粘扣等重点部位开展了32批次分部位检测。根据检测结果,368批次成品样品和32批次分部位样品,均未检出甲酰胺。

(二)对相关自媒体博主检测剩余纸尿裤样品进行复检。调查组将小红书平台自媒体账号“靠谱老王”博主王某某检测剩余的纸尿裤样品进行封存,组织中国疾病预防控制中心、中国质量检验检测科学研究院、北京市疾病预防控制中心对其中包装完整的样品进行复检,复检的15个品牌58批次样品均未检出甲酰胺。工业和信息化部组织中国科学院深圳先进技术研究院、中国质量检验检测科学研究院等单位专家和重要相关方代表,当面与王某某进行技术交流,对其检测过程进行完整复现,发现其存在检测方法未经过严格的方法确认、未将检测到的质荷比数据与甲酰胺精确质量数进行偏差评估等多方面问题,无法得出检出甲酰胺的结论。

(三)对婴幼儿纸尿裤生产企业开展现场检查。舆情发生后,国家疾控局立即部署地方疾控部门对全部168家婴幼儿纸尿裤生产企业(含代工企业)进行现场监督检查。从检查情况看,受检企业均符合消毒产品生产企业卫生规范要求,未发现生产工艺及原材料中存在添加或含有甲酰胺的情况。

二、关于舆情反映的血液中甲酰胺检测问题

(一)对山东省公共卫生临床中心质谱研究与临床应用中心进行调查核实。舆情发生前,国内外均未见血液中甲酰胺检测方法的有关报道。经调查核实,山东省公共卫生临床中心质谱研究与临床应用中心(以下简称山东质谱中心)开展的血液中甲酰胺检测于2026年6月开始,处于初步研究阶段。该中心负责人于某某及其助手李某某均承认,其检测方法尚不完善。

(二)对山东质谱中心开展的血液中甲酰胺检测结果进行研判。经国家卫生健康委临床检验中心、山东省疾病预防控制中心等单位专家对山东质谱中心开展的血液中甲酰胺检测进行核查,发现其相关检测存在空白基质检出相同信号、样本检测信噪比未达到定性分析基本要求、人为取舍检测数据点、删除原始数据等多方面问题,专家一致认为其开展的血液甲酰胺检测过程不可靠,检测结论不可信。

(三)对山东质谱中心血液样本进行复检。调查组封存了山东质谱中心用于检测的210份血液样本,带回北京进行复检。国家卫生健康委临床检验中心、中国疾病预防控制中心、中国医科大学附属第一医院、北京协和医院等单位院士、专家反复论证和验证,形成了血液样本甲酰胺检测方法。同时,用该方法对从山东质谱中心封存带回的血液样本进行平行复检,210份血液样本均未检出甲酰胺。

三、关于婴幼儿纸尿裤检出甲酰胺其他相关信息的调查核实情况

(一)对合肥广测产品检测研究所有限公司检测情况进行调查核实。经调查核实,舆情反映在送检婴幼儿纸尿裤中检出甲酰胺的第三方专业检测机构为合肥广测产品检测研究所有限公司(以下简称合肥广测),合肥广测因不具备甲酰胺检测能力,将检测任务委托给苏州谱择检测技术有限公司(以下简称苏州谱择)。工业和信息化部组织专家对苏州谱择提供的检测数据进行分析研判,认为存在未开展空白样和平行样检测、未与标准物质的出峰时间加以比对、样品谱图和甲酰胺标准谱图匹配度只有7%等多方面问题,检测过程及判定依据不严谨,无法得出检出甲酰胺的结论。

(二)对联信检测(江苏)有限公司检测情况进行调查核实。6月25日,两份联信检测(江苏)有限公司(以下简称联信检测)的婴幼儿纸尿裤检测报告截图在网上流出,标注的甲酰胺检出值分别为414mg/kg和384mg/kg,引发舆论关注。经调查核实,网传报告为联信检测发给委托人核对样品和客户信息的电子稿;该公司专业审核人员在审核中,发现数据结果所对应物质特征峰的保留时间与甲酰胺不同,判定并未检出甲酰胺。该公司随即与委托人沟通,撤回了报告电子稿,并公开声明网传的两份报告无效。

(三)对“沈博健康测评”博主沈某检出甲酰胺情况进行调查核实。6月20日后,自媒体账号“沈博健康测评”在小红书、微信视频号、抖音等平台发布多期纸尿裤测评视频,称在多款婴幼儿纸尿裤中检出甲酰胺。经调查核实,该自媒体账号的博主为沈某,其不具备相应的检测能力,实际委托赵某某进行检测。经调查组组织专家对沈某、赵某某检测情况进行分析研判,认为其相关检测存在检测方法未进行方法确认、未开展空白样和平行样检测、定性原则不明确、删除原始数据等问题,无法得出检出甲酰胺的结论。

婴幼儿纸尿裤甲酰胺检测是严肃、专业的检验检测活动,甲酰胺相关健康危害更需要审慎客观地开展研究。对调查发现的医疗机构和人员违规问题,山东省卫生健康委已依据有关规定作出处理。有关部门将继续加强婴幼儿用品监管,指导生产企业健全质量管理体系,严格落实卫生安全主体责任,欢迎社会各界积极参与,共同营造安全放心的消费环境。

婴幼儿纸尿裤甲酰胺问题联合调查组

2026年10月15日

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

本文首发于 亿邦动力 官方网站

文章来源:亿邦动力

广告
微信
朋友圈

FAQ回顾

婴幼儿纸尿裤中的甲酰胺问题现在有官方定论了吗?

2026年10月15日,市场监管总局、工业和信息化部、国家卫生健康委、国家疾控局联合调查组通报,国内全部168家婴幼儿纸尿裤生产企业的180个品牌368批次成品样品和32批次重点部位样品均未检出甲酰胺,现场检查也未发现生产工艺及原材料中添加或含有甲酰胺。

为什么自媒体测评纸尿裤检出甲酰胺,官方抽检却没有?

官方调查发现,相关自媒体博主和第三方检测存在检测方法未经过严格方法确认、未开展空白样和平行样检测、样品谱图与甲酰胺标准谱图匹配度低、删除原始数据等问题,无法得出检出甲酰胺的结论;联信检测的网传报告也被判定并未检出甲酰胺。

血液中甲酰胺检测结果可信吗?

官方调查认为不可信。山东质谱中心开展的血液中甲酰胺检测尚处初步研究阶段,存在空白基质检出相同信号、样本信噪比未达定性分析要求、人为取舍数据点和删除原始数据等问题;封存的210份血液样本经权威机构复检均未检出甲酰胺。

纸尿裤生产企业需要符合哪些卫生规范?

根据四部门通报,国内全部168家婴幼儿纸尿裤生产企业(含代工企业)经现场监督检查,均符合消毒产品生产企业卫生规范要求,未发现生产工艺及原材料中存在添加或含有甲酰胺的情况。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0